カテゴリー： Market Monitor Global, 世界, 医療/バイオ

続発性副甲状腺機能亢進症治療薬の世界市場見通し2023年-2029年

◆英語タイトル：Secondary Hyperparathyroidism Drug Market, Global Outlook and Forecast 2023-2029
	◆商品コード：MMG23LY8652 ◆発行会社（リサーチ会社）：Market Monitor Global ◆発行日：2023年7月（※2025年版があります。お問い合わせください。） ◆ページ数：79 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後2-3営業日） ◆調査対象地域：グローバル ◆産業分野：医薬品＆ヘルスケア

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥468,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥608,400	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥702,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Global Secondary Hyperparathyroidism Drug Market 調査レポートは次の情報を含め、グローバルにおけるの続発性副甲状腺機能亢進症治療薬市場規模と予測を収録しています。・世界の続発性副甲状腺機能亢進症治療薬市場：売上、2018年-2023年、2024年-2029年
・世界の続発性副甲状腺機能亢進症治療薬市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の続発性副甲状腺機能亢進症治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「エボカルセット」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

続発性副甲状腺機能亢進症治療薬のグローバル主要企業は、Deltanoid Pharmaceuticals Inc、 EA Pharma Co Ltd、 Lupin Ltd、 Mitsubishi Tanabe Pharma Corp、 OPKO Health Inc、 Takedaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、続発性副甲状腺機能亢進症治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の続発性副甲状腺機能亢進症治療薬市場：タイプ別、2018年-2023年、2024年-2029年
世界の続発性副甲状腺機能亢進症治療薬市場：タイプ別市場シェア、2022年
・エボカルセット、LNP-1892、AJT-240、シナカルセット塩酸塩、CTA-091、その他

世界の続発性副甲状腺機能亢進症治療薬市場：用途別、2018年-2023年、2024年-2029年
世界の続発性副甲状腺機能亢進症治療薬市場：用途別市場シェア、2022年
・病院、診療所、その他

世界の続発性副甲状腺機能亢進症治療薬市場：地域・国別、2018年-2023年、2024年-2029年
世界の続発性副甲状腺機能亢進症治療薬市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における続発性副甲状腺機能亢進症治療薬のグローバル売上、2018年-2023年
・主要企業における続発性副甲状腺機能亢進症治療薬のグローバル売上シェア、2022年
・主要企業における続発性副甲状腺機能亢進症治療薬のグローバル販売量、2018年-2023年
・主要企業における続発性副甲状腺機能亢進症治療薬のグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Deltanoid Pharmaceuticals Inc、 EA Pharma Co Ltd、 Lupin Ltd、 Mitsubishi Tanabe Pharma Corp、 OPKO Health Inc、 Takeda

*************************************************************

・調査・分析レポートの概要
続発性副甲状腺機能亢進症治療薬市場の定義
市場セグメント
世界の続発性副甲状腺機能亢進症治療薬市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の続発性副甲状腺機能亢進症治療薬市場規模
世界の続発性副甲状腺機能亢進症治療薬市場規模：2022年 VS 2029年
世界の続発性副甲状腺機能亢進症治療薬市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの続発性副甲状腺機能亢進症治療薬の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の続発性副甲状腺機能亢進症治療薬製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：エボカルセット、LNP-1892、AJT-240、シナカルセット塩酸塩、CTA-091、その他
続発性副甲状腺機能亢進症治療薬のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：病院、診療所、その他
続発性副甲状腺機能亢進症治療薬の用途別グローバル売上・予測

・地域別市場分析
地域別続発性副甲状腺機能亢進症治療薬市場規模 2022年と2029年
地域別続発性副甲状腺機能亢進症治療薬売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報（企業概要、事業概要、主要製品、売上、ニュースなど）
Deltanoid Pharmaceuticals Inc、 EA Pharma Co Ltd、 Lupin Ltd、 Mitsubishi Tanabe Pharma Corp、 OPKO Health Inc、 Takeda
...

This report aims to provide a comprehensive presentation of the global market for Secondary Hyperparathyroidism Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Secondary Hyperparathyroidism Drug. This report contains market size and forecasts of Secondary Hyperparathyroidism Drug in global, including the following market information:
Global Secondary Hyperparathyroidism Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Secondary Hyperparathyroidism Drug Market Sales, 2018-2023, 2024-2029, (K Pcs)
Global top five Secondary Hyperparathyroidism Drug companies in 2022 (%)
The global Secondary Hyperparathyroidism Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Evocalcet Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Secondary Hyperparathyroidism Drug include Deltanoid Pharmaceuticals Inc, EA Pharma Co Ltd, Lupin Ltd, Mitsubishi Tanabe Pharma Corp, OPKO Health Inc and Takeda, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Secondary Hyperparathyroidism Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Secondary Hyperparathyroidism Drug Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Secondary Hyperparathyroidism Drug Market Segment Percentages, by Type, 2022 (%)
Evocalcet
LNP-1892
AJT-240
Cinacalcet Hydrochloride
CTA-091
Others
Global Secondary Hyperparathyroidism Drug Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Secondary Hyperparathyroidism Drug Market Segment Percentages, by Application, 2022 (%)
Hospital
Clinic
Others
Global Secondary Hyperparathyroidism Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Pcs)
Global Secondary Hyperparathyroidism Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Secondary Hyperparathyroidism Drug revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Secondary Hyperparathyroidism Drug revenues share in global market, 2022 (%)
Key companies Secondary Hyperparathyroidism Drug sales in global market, 2018-2023 (Estimated), (K Pcs)
Key companies Secondary Hyperparathyroidism Drug sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Deltanoid Pharmaceuticals Inc
EA Pharma Co Ltd
Lupin Ltd
Mitsubishi Tanabe Pharma Corp
OPKO Health Inc
Takeda
Outline of Major Chapters:
Chapter 1: Introduces the definition of Secondary Hyperparathyroidism Drug, market overview.
Chapter 2: Global Secondary Hyperparathyroidism Drug market size in revenue and volume.
Chapter 3: Detailed analysis of Secondary Hyperparathyroidism Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Secondary Hyperparathyroidism Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Secondary Hyperparathyroidism Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Secondary Hyperparathyroidism Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Secondary Hyperparathyroidism Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Secondary Hyperparathyroidism Drug Overall Market Size
2.1 Global Secondary Hyperparathyroidism Drug Market Size: 2022 VS 2029
2.2 Global Secondary Hyperparathyroidism Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Secondary Hyperparathyroidism Drug Sales: 2018-2029
3 Company Landscape
3.1 Top Secondary Hyperparathyroidism Drug Players in Global Market
3.2 Top Global Secondary Hyperparathyroidism Drug Companies Ranked by Revenue
3.3 Global Secondary Hyperparathyroidism Drug Revenue by Companies
3.4 Global Secondary Hyperparathyroidism Drug Sales by Companies
3.5 Global Secondary Hyperparathyroidism Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Secondary Hyperparathyroidism Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Secondary Hyperparathyroidism Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 Secondary Hyperparathyroidism Drug Players in Global Market
3.8.1 List of Global Tier 1 Secondary Hyperparathyroidism Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 Secondary Hyperparathyroidism Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Secondary Hyperparathyroidism Drug Market Size Markets, 2022 & 2029
4.1.2 Evocalcet
4.1.3 LNP-1892
4.1.4 AJT-240
4.1.5 Cinacalcet Hydrochloride
4.1.6 CTA-091
4.1.7 Others
4.2 By Type – Global Secondary Hyperparathyroidism Drug Revenue & Forecasts
4.2.1 By Type – Global Secondary Hyperparathyroidism Drug Revenue, 2018-2023
4.2.2 By Type – Global Secondary Hyperparathyroidism Drug Revenue, 2024-2029
4.2.3 By Type – Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
4.3 By Type – Global Secondary Hyperparathyroidism Drug Sales & Forecasts
4.3.1 By Type – Global Secondary Hyperparathyroidism Drug Sales, 2018-2023
4.3.2 By Type – Global Secondary Hyperparathyroidism Drug Sales, 2024-2029
4.3.3 By Type – Global Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
4.4 By Type – Global Secondary Hyperparathyroidism Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Secondary Hyperparathyroidism Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.1.4 Others
5.2 By Application – Global Secondary Hyperparathyroidism Drug Revenue & Forecasts
5.2.1 By Application – Global Secondary Hyperparathyroidism Drug Revenue, 2018-2023
5.2.2 By Application – Global Secondary Hyperparathyroidism Drug Revenue, 2024-2029
5.2.3 By Application – Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
5.3 By Application – Global Secondary Hyperparathyroidism Drug Sales & Forecasts
5.3.1 By Application – Global Secondary Hyperparathyroidism Drug Sales, 2018-2023
5.3.2 By Application – Global Secondary Hyperparathyroidism Drug Sales, 2024-2029
5.3.3 By Application – Global Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
5.4 By Application – Global Secondary Hyperparathyroidism Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Secondary Hyperparathyroidism Drug Market Size, 2022 & 2029
6.2 By Region – Global Secondary Hyperparathyroidism Drug Revenue & Forecasts
6.2.1 By Region – Global Secondary Hyperparathyroidism Drug Revenue, 2018-2023
6.2.2 By Region – Global Secondary Hyperparathyroidism Drug Revenue, 2024-2029
6.2.3 By Region – Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
6.3 By Region – Global Secondary Hyperparathyroidism Drug Sales & Forecasts
6.3.1 By Region – Global Secondary Hyperparathyroidism Drug Sales, 2018-2023
6.3.2 By Region – Global Secondary Hyperparathyroidism Drug Sales, 2024-2029
6.3.3 By Region – Global Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Secondary Hyperparathyroidism Drug Revenue, 2018-2029
6.4.2 By Country – North America Secondary Hyperparathyroidism Drug Sales, 2018-2029
6.4.3 US Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.4.4 Canada Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.4.5 Mexico Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Secondary Hyperparathyroidism Drug Revenue, 2018-2029
6.5.2 By Country – Europe Secondary Hyperparathyroidism Drug Sales, 2018-2029
6.5.3 Germany Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5.4 France Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5.5 U.K. Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5.6 Italy Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5.7 Russia Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5.8 Nordic Countries Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.5.9 Benelux Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Secondary Hyperparathyroidism Drug Revenue, 2018-2029
6.6.2 By Region – Asia Secondary Hyperparathyroidism Drug Sales, 2018-2029
6.6.3 China Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.6.4 Japan Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.6.5 South Korea Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.6.6 Southeast Asia Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.6.7 India Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Secondary Hyperparathyroidism Drug Revenue, 2018-2029
6.7.2 By Country – South America Secondary Hyperparathyroidism Drug Sales, 2018-2029
6.7.3 Brazil Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.7.4 Argentina Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Secondary Hyperparathyroidism Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Secondary Hyperparathyroidism Drug Sales, 2018-2029
6.8.3 Turkey Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.8.4 Israel Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.8.5 Saudi Arabia Secondary Hyperparathyroidism Drug Market Size, 2018-2029
6.8.6 UAE Secondary Hyperparathyroidism Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Deltanoid Pharmaceuticals Inc
7.1.1 Deltanoid Pharmaceuticals Inc Company Summary
7.1.2 Deltanoid Pharmaceuticals Inc Business Overview
7.1.3 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Major Product Offerings
7.1.4 Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Sales and Revenue in Global (2018-2023)
7.1.5 Deltanoid Pharmaceuticals Inc Key News & Latest Developments
7.2 EA Pharma Co Ltd
7.2.1 EA Pharma Co Ltd Company Summary
7.2.2 EA Pharma Co Ltd Business Overview
7.2.3 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Major Product Offerings
7.2.4 EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Sales and Revenue in Global (2018-2023)
7.2.5 EA Pharma Co Ltd Key News & Latest Developments
7.3 Lupin Ltd
7.3.1 Lupin Ltd Company Summary
7.3.2 Lupin Ltd Business Overview
7.3.3 Lupin Ltd Secondary Hyperparathyroidism Drug Major Product Offerings
7.3.4 Lupin Ltd Secondary Hyperparathyroidism Drug Sales and Revenue in Global (2018-2023)
7.3.5 Lupin Ltd Key News & Latest Developments
7.4 Mitsubishi Tanabe Pharma Corp
7.4.1 Mitsubishi Tanabe Pharma Corp Company Summary
7.4.2 Mitsubishi Tanabe Pharma Corp Business Overview
7.4.3 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Major Product Offerings
7.4.4 Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Sales and Revenue in Global (2018-2023)
7.4.5 Mitsubishi Tanabe Pharma Corp Key News & Latest Developments
7.5 OPKO Health Inc
7.5.1 OPKO Health Inc Company Summary
7.5.2 OPKO Health Inc Business Overview
7.5.3 OPKO Health Inc Secondary Hyperparathyroidism Drug Major Product Offerings
7.5.4 OPKO Health Inc Secondary Hyperparathyroidism Drug Sales and Revenue in Global (2018-2023)
7.5.5 OPKO Health Inc Key News & Latest Developments
7.6 Takeda
7.6.1 Takeda Company Summary
7.6.2 Takeda Business Overview
7.6.3 Takeda Secondary Hyperparathyroidism Drug Major Product Offerings
7.6.4 Takeda Secondary Hyperparathyroidism Drug Sales and Revenue in Global (2018-2023)
7.6.5 Takeda Key News & Latest Developments
8 Global Secondary Hyperparathyroidism Drug Production Capacity, Analysis
8.1 Global Secondary Hyperparathyroidism Drug Production Capacity, 2018-2029
8.2 Secondary Hyperparathyroidism Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global Secondary Hyperparathyroidism Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Secondary Hyperparathyroidism Drug Supply Chain Analysis
10.1 Secondary Hyperparathyroidism Drug Industry Value Chain
10.2 Secondary Hyperparathyroidism Drug Upstream Market
10.3 Secondary Hyperparathyroidism Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Secondary Hyperparathyroidism Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Secondary Hyperparathyroidism Drug in Global Market
Table 2. Top Secondary Hyperparathyroidism Drug Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Secondary Hyperparathyroidism Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Secondary Hyperparathyroidism Drug Revenue Share by Companies, 2018-2023
Table 5. Global Secondary Hyperparathyroidism Drug Sales by Companies, (K Pcs), 2018-2023
Table 6. Global Secondary Hyperparathyroidism Drug Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Secondary Hyperparathyroidism Drug Price (2018-2023) & (USD/Pcs)
Table 8. Global Manufacturers Secondary Hyperparathyroidism Drug Product Type
Table 9. List of Global Tier 1 Secondary Hyperparathyroidism Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Secondary Hyperparathyroidism Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Secondary Hyperparathyroidism Drug Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Secondary Hyperparathyroidism Drug Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Secondary Hyperparathyroidism Drug Sales (K Pcs), 2018-2023
Table 15. By Type - Global Secondary Hyperparathyroidism Drug Sales (K Pcs), 2024-2029
Table 16. By Application – Global Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Secondary Hyperparathyroidism Drug Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Secondary Hyperparathyroidism Drug Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Secondary Hyperparathyroidism Drug Sales (K Pcs), 2018-2023
Table 20. By Application - Global Secondary Hyperparathyroidism Drug Sales (K Pcs), 2024-2029
Table 21. By Region – Global Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Secondary Hyperparathyroidism Drug Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Secondary Hyperparathyroidism Drug Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Secondary Hyperparathyroidism Drug Sales (K Pcs), 2018-2023
Table 25. By Region - Global Secondary Hyperparathyroidism Drug Sales (K Pcs), 2024-2029
Table 26. By Country - North America Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2018-2023
Table 29. By Country - North America Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2024-2029
Table 30. By Country - Europe Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2018-2023
Table 33. By Country - Europe Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2024-2029
Table 34. By Region - Asia Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2018-2023
Table 37. By Region - Asia Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2024-2029
Table 38. By Country - South America Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2018-2023
Table 41. By Country - South America Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2024-2029
Table 42. By Country - Middle East & Africa Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2018-2023
Table 45. By Country - Middle East & Africa Secondary Hyperparathyroidism Drug Sales, (K Pcs), 2024-2029
Table 46. Deltanoid Pharmaceuticals Inc Company Summary
Table 47. Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Product Offerings
Table 48. Deltanoid Pharmaceuticals Inc Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 49. Deltanoid Pharmaceuticals Inc Key News & Latest Developments
Table 50. EA Pharma Co Ltd Company Summary
Table 51. EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Product Offerings
Table 52. EA Pharma Co Ltd Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 53. EA Pharma Co Ltd Key News & Latest Developments
Table 54. Lupin Ltd Company Summary
Table 55. Lupin Ltd Secondary Hyperparathyroidism Drug Product Offerings
Table 56. Lupin Ltd Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 57. Lupin Ltd Key News & Latest Developments
Table 58. Mitsubishi Tanabe Pharma Corp Company Summary
Table 59. Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Product Offerings
Table 60. Mitsubishi Tanabe Pharma Corp Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 61. Mitsubishi Tanabe Pharma Corp Key News & Latest Developments
Table 62. OPKO Health Inc Company Summary
Table 63. OPKO Health Inc Secondary Hyperparathyroidism Drug Product Offerings
Table 64. OPKO Health Inc Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 65. OPKO Health Inc Key News & Latest Developments
Table 66. Takeda Company Summary
Table 67. Takeda Secondary Hyperparathyroidism Drug Product Offerings
Table 68. Takeda Secondary Hyperparathyroidism Drug Sales (K Pcs), Revenue (US$, Mn) and Average Price (USD/Pcs) (2018-2023)
Table 69. Takeda Key News & Latest Developments
Table 70. Secondary Hyperparathyroidism Drug Production Capacity (K Pcs) of Key Manufacturers in Global Market, 2021-2023 (K Pcs)
Table 71. Global Secondary Hyperparathyroidism Drug Capacity Market Share of Key Manufacturers, 2021-2023
Table 72. Global Secondary Hyperparathyroidism Drug Production by Region, 2018-2023 (K Pcs)
Table 73. Global Secondary Hyperparathyroidism Drug Production by Region, 2024-2029 (K Pcs)
Table 74. Secondary Hyperparathyroidism Drug Market Opportunities & Trends in Global Market
Table 75. Secondary Hyperparathyroidism Drug Market Drivers in Global Market
Table 76. Secondary Hyperparathyroidism Drug Market Restraints in Global Market
Table 77. Secondary Hyperparathyroidism Drug Raw Materials
Table 78. Secondary Hyperparathyroidism Drug Raw Materials Suppliers in Global Market
Table 79. Typical Secondary Hyperparathyroidism Drug Downstream
Table 80. Secondary Hyperparathyroidism Drug Downstream Clients in Global Market
Table 81. Secondary Hyperparathyroidism Drug Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Secondary Hyperparathyroidism Drug Segment by Type in 2022
Figure 2. Secondary Hyperparathyroidism Drug Segment by Application in 2022
Figure 3. Global Secondary Hyperparathyroidism Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Secondary Hyperparathyroidism Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Secondary Hyperparathyroidism Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. Secondary Hyperparathyroidism Drug Sales in Global Market: 2018-2029 (K Pcs)
Figure 8. The Top 3 and 5 Players Market Share by Secondary Hyperparathyroidism Drug Revenue in 2022
Figure 9. By Type - Global Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 11. By Type - Global Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 12. By Type - Global Secondary Hyperparathyroidism Drug Price (USD/Pcs), 2018-2029
Figure 13. By Application - Global Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 15. By Application - Global Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 16. By Application - Global Secondary Hyperparathyroidism Drug Price (USD/Pcs), 2018-2029
Figure 17. By Region - Global Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 20. By Region - Global Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 21. By Country - North America Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 22. By Country - North America Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 23. US Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 28. Germany Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 29. France Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 37. China Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 41. India Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 43. By Country - South America Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 44. Brazil Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Secondary Hyperparathyroidism Drug Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Secondary Hyperparathyroidism Drug Sales Market Share, 2018-2029
Figure 48. Turkey Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Secondary Hyperparathyroidism Drug Revenue, (US$, Mn), 2018-2029
Figure 52. Global Secondary Hyperparathyroidism Drug Production Capacity (K Pcs), 2018-2029
Figure 53. The Percentage of Production Secondary Hyperparathyroidism Drug by Region, 2022 VS 2029
Figure 54. Secondary Hyperparathyroidism Drug Industry Value Chain
Figure 55. Marketing Channels

※参考情報

続発性副甲状腺機能亢進症は、主に慢性腎疾患に関連して発生する病態であり、腎機能の低下に伴って副甲状腺ホルモン（PTH）の分泌が過剰になる状態を指します。この病態は、カルシウムとリンの代謝の異常を引き起こすことから、しばしば骨や血管系に悪影響を与えることがあります。そのため、続発性副甲状腺機能亢進症の治療は、腎疾患患者において重要な治療目標の一つとなっています。

この疾患の特徴としては、副甲状腺ホルモンの過剰な分泌が挙げられます。副甲状腺ホルモンは血中カルシウム濃度を調整する役割を担っており、通常は血中カルシウムが低下すると分泌が増加し、高まると抑制されます。しかし、慢性腎疾患が進行するとリンの排泄が低下し、それがカルシウムの欠乏を引き起こすことから、PTHの分泌が続きます。この結果、骨からのカルシウムの動員や腎臓でのカルシウム再吸収が促進されますが、やがて摂取したカルシウムでは補えない状態になります。

このような背景から、続発性副甲状腺機能亢進症の治療薬について述べることが必要です。これらの薬剤は、一般的に次のような種類に分類されます。

1. **リン吸着薬**：患者の腎機能が低下している場合、リンの排泄が不十分になるため、リン酸塩の蓄積が問題になります。リン吸着薬は、腸管でリンを吸着し排泄を促進することで血中リン濃度を低下させます。例としては、セベラマーやランタンなどがあります。

2. **ビタミンD誘導体**：慢性腎疾患患者ではビタミンDの活性型であるカルシトリオールの合成が低下します。ビタミンD誘導体は、腸管からのカルシウム吸収を促進し、PTHの分泌を低下させる作用があります。アコカシフェロールやカルシトリオールなどが例です。

3. **パラセタモール**: 最近の研究では、特定のパラセタモールが副甲状腺機能を抑制することが示されています。これが臨床的に有用かどうかは今後の研究に期待されます。

4. **副甲状腺ホルモン抑制薬**：新たに開発された薬剤として副甲状腺ホルモンの作用を特異的に抑制するものがあります。これにより、PTHの過剰分泌を直接的に抑えることが期待されています。

治療の目的は、PTHの正常値に戻し、骨代謝の正常化を図ることです。これにより、骨の健康を維持し、骨粗しょう症や血管の合併症を防ぐことができるため、患者の生活の質を向上させる重要な役割を果たします。

また、治療の選択肢は患者の腎機能の状態や合併症によって異なるため、個々の患者に結果を求めた治療法の選択が求められます。これには、患者の背景や治療歴を考慮し、チーム医療に基づくアプローチが効果的です。

関連技術として、血液検査や画像検査が重要です。定期的な血液検査によってカルシウム、リン、PTHのレベルをモニタリングし、治療の適切な調整を行います。また、骨密度測定や骨代謝マーカーの評価も、骨の健康状態を把握するために有用です。

加えて、栄養管理も重要な要素です。低リン食や適切なカルシウム摂取により、病態の進行を抑えることができます。患者教育も不可欠で、患者が自らの病状を理解し、日常生活における選択ができるようにすることが求められます。

結論として、続発性副甲状腺機能亢進症に対する治療は複雑であり、患者の個々のニーズに応じた多角的なアプローチが必要です。医療チームによる適切な管理と、最新の治療薬の使用が、患者のQoL（生活の質）の向上に大いに寄与することでしょう。今後の研究が、より効果的な治療薬の開発や新たな治療戦略の確立に向けて進むことを期待します。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 続発性副甲状腺機能亢進症治療薬の世界市場見通し2023年-2029年(Secondary Hyperparathyroidism Drug Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

続発性副甲状腺機能亢進症治療薬の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp